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ATM phosphorylation of Mdm2-S394 is required for
robust p53 stabilization and activation in DNA-
damaged cells. We have now utilized Mdm2S394A
knockin mice to determine that phosphorylation
of Mdm2-S394 regulates p53 activity and the DNA
damage response in lymphatic tissues in vivo
by modulating Mdm2 stability. Mdm2-S394 phos-
phorylation delays lymphomagenesis in Em-myc
transgenic mice, and preventing Mdm2-S394
phosphorylation obviates the need for p53 mutation
in Myc-driven tumorigenesis. However, irradiated
Mdm2S394A mice also have increased hematopoietic
stem and progenitor cell functions, and we observed
decreased lymphomagenesis in sub-lethally irradi-
ated Mdm2S394A mice. These findings document
contrasting effects of ATM-Mdm2 signaling on p53
tumor suppression and reveal that destabilizing
Mdm2 by promoting its phosphorylation by ATM
would be effective in treating oncogene-induced
malignancies, while inhibiting Mdm2-S394 phos-
phorylation during radiation exposure or chemo-
therapy would ameliorate bone marrow failure and
prevent the development of secondary hematologi-
cal malignancies.INTRODUCTION
It is widely accepted that the p53 tumor suppressor protein func-
tions primarily as a transcription factor, capable of promoting or
repressing the transcription of a multitude of genes (Beckerman
and Prives, 2010). Proper coordination of p53-responsive gene
expression plays an important role in tumor suppression, as evi-
denced by the rapid development of tumors in mice lacking p53
(Donehower et al., 1992) and by the fact that most human can-
cers harbor mutations in p53 or in key regulators of p53 signaling
(Soussi and Be´roud, 2001). The tumor suppressive capacity of
p53 has been traditionally attributed to its ability to inhibit cell2618 Cell Reports 16, 2618–2629, September 6, 2016 ª 2016 The Au
This is an open access article under the CC BY-NC-ND license (http://proliferation or promote apoptosis, as limiting or eliminating cells
bearing genetic lesions would obviously prevent the propagation
and accumulation of genetic errors and the formation or pro-
gression of tumorigenesis. However, p53 tumor suppressive
mechanisms distinct from p53-mediated growth arrest and
apoptosis have been recently proposed, suggesting an even
broader contribution of p53 activities to tumor suppression
(Brady et al., 2011; Li et al., 2012).
Because deregulated growth arrest and apoptosis is detri-
mental to embryogenesis and normal cell growth, the activities
of p53 are strictly regulated in non-damaged cells and tissues.
Basal levels of p53 are low, and this transcription factor is largely
inactive under homeostatic conditions. In contrast, p53 is rapidly
stabilized and activated in response to a multitude of stresses,
including activated oncogenes, hypoxia, ribosomal stress, and
DNA damage. The chief negative regulator of p53 stabilization
and activity is the Mdm2 oncoprotein, which can bind and
mask the transactivation domain of p53 and function as an E3
ubiquitin ligase capable of directing p53 nuclear export and
proteosomal degradation (Momand et al., 1992; Oliner et al.,
1993; Haupt et al., 1997; Honda et al., 1997; Kubbutat et al.,
1997). The central role of Mdm2 in regulating p53 activity is
best illustrated by studies using Mdm2-conditional mouse
models that identified roles for Mdm2 in regulating p53-depen-
dent cell growth arrest or apoptosis in various tissues (Gannon
and Jones, 2012) and p53-dependent lethality of Mdm2 null
mice during early embryogenesis (Jones et al., 1995; Montes
de Oca Luna et al., 1995).
Similar to Mdm2, the homologous protein MdmX (Mdm4) is
also capable of binding p53 and inhibiting p53 transactivation
of target genes (Shvarts et al., 1996), and mice null for MdmX
display a similar p53-dependent embryonic lethality, albeit at a
slightly later time during development (Parant et al., 2001; Mi-
gliorini et al., 2002). Unlike Mdm2, MdmX does not possess
the ability to directly ubiquitinate p53 (Jackson and Berberich,
2000). However, Mdm2 and MdmX have been shown to interact
via their C-terminal RING domains, and this heterodimerization
promotes maximal Mdm2 E3 ligase activity toward p53
(Tanimura et al., 1999; Sharp et al., 1999, Kawai et al., 2007).
Recently, a series of Mdm2 and MdmX knockin mouse models
have been generated that display altered Mdm2-MdmX interac-
tions or Mdm2 E3 ligase activity (Itahana et al., 2007; Pant et al.,thor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
2011; Huang et al., 2011; Tollini et al., 2014). Analyses of these
various models have revealed that Mdm2-MdmX interactions
are critical in inhibiting p53 activity during development and tis-
sue homeostasis, whereas the E3 ligase function of Mdm2 is crit-
ical in regulating p53 protein and activity levels in cellular and
organismal response to DNA damage (Tollini et al., 2014).
Inhibition of p53 levels and activities byMDMproteins must be
interrupted in order for p53 to become elevated and activated in
response to DNA damage or other forms of stress (Meek, 2015).
During the DNA damage response (DDR), Mdm2-p53 signaling
is mediated by DNA-damage-activated kinases such as ATM
(ataxia telangiectasia mutated). Upon sensing double-stranded
DNA breaks, the PI3K-related ATM becomes activated and
directly or indirectly induces phosphorylation of a multitude
of proteins involved in the damage response, including p53,
Mdm2, and MdmX (Shieh et al., 1997, 2000; Maya et al., 2001;
Pereg et al., 2005; Chen et al., 2005). Initial biochemical and
cell-based studies suggested that ATM-mediated phosphoryla-
tion of two key residues on p53, Ser18 and Ser23 (human Ser15
and Ser20), could account for p53 stabilization and activation
following DNA damage. However, analysis of genetically engi-
neered mouse models revealed that these phosphorylation
events were insufficient to account for the full effects of DNA
damage on Mdm2-p53 signaling or p53 tumor suppression
(Wu et al., 2002; Chao et al., 2003, 2006; Sluss et al., 2004).
We have previously reported the generation and initial character-
ization of a mouse model (Mdm2S394A mice), wherein ATM
phosphorylation of Mdm2 at serine residue 394 was abolished
(Gannon et al., 2012). Cells and tissues in Mdm2S394A mice
display profound defects in DNA-damage-induced p53 protein
stabilization and p53 target gene activation. This failure to
induce a robust p53 response translates to less p53-depen-
dent apoptosis in hematopoietic tissues, radioresistance, and
increased spontaneous lymphomagenesis. Regulation of the
amplitude and duration of the p53-induced DDR in Mdm2S394A
cells and mice underscores the importance of ATM phosphory-
lation of Mdm2 in the DDR.
Several in vitro studies have suggested that ATM phosphory-
lation of Mdm2 governs p53 stability and/or activity following
DNA damage by regulating p53 degradation and nuclear export,
Mdm2 autodegradation, and Mdm2 oligomerization and E3
processivity (Maya et al., 2001; Stommel andWahl, 2004; Cheng
et al., 2009). In our present study, we explore in vivo the mecha-
nism by which Mdm2 phosphorylation alters p53 functions in a
radiosensitive tissue. Furthermore, we have sought to address
whether ATM-Mdm2-p53 signaling in mice impacts tumorigen-
esis induced by activated oncogenes or ionizing radiation (IR),
and we explore the role of ATM-Mdm2 signaling in promoting
IR-mediated bone marrow failure. Our results indicate that
Mdm2phosphorylation has dramatically different, stress-depen-
dent effects in tumorigenesis.
RESULTS
ATM-Mdm2 Signaling Regulates the p53 Response in
Lymphatic Tissues
To further explore the effects of Mdm2 Ser394 phosphorylation
on p53 protein levels and activity in vivo, we analyzed thymi ofmice treated with a low dose (1.75 Gy) of IR. Although p53 pro-
tein levels were elevated in the thymus of Mdm2S394A mice at
3 hr and 6 hr following IR, there was considerably less total
p53 protein and phosphorylated p53 (S18) in treatedMdm2S394A
mice than in irradiated wild-type (WT) mice (Figure 1A). This is
similar to what we observed previously in these mice using
higher dosages of IR (Gannon et al., 2012). However, we also
noted that basal levels of p53 appeared slightly lower in
Mdm2S394A thymi than in WT thymi, and more Mdm2 protein ap-
peared to be present in Mdm2S394A thymi in absence of acute
DNA damage and following IR treatment (Figure 1A). There
was a significant decrease in WT Mdm2 protein levels in whole
thymus following DNA damage, an observation that has been
made in cell culture settings by several groups (Stommel and
Wahl, 2004; Itahana et al., 2007; Inuzuka et al., 2010; Malonia
et al., 2015). However, Mdm2 protein levels appeared to diminish
after IR at a lesser rate inMdm2S394A thymus than in WT thymus.
To more definitively quantify the observed differences in thymic
Mdm2 and p53 levels, we analyzed biological triplicates of un-
treated and irradiated WT andMdm2S394A thymi. This confirmed
that Mdm2 protein levels were higher in Mdm2S394A thymi both
before and after treatment and that the IR-induced relative
decrease in Mdm2 protein levels was far less in Mdm2S394A
thymi (Figure 1B). In contrast, the reduction of MdmX levels
induced by DNA damage (Wang et al., 2009) appears to be
similar in WT andMdm2S394A thymi. Though not statistically sig-
nificant, p53 levels are slightly lower in untreated Mdm2S394A
thymi (Figure 1B, bottom) and are significantly lower in irradiated
Mdm2S394A thymi. Although p53 target gene expression was
similar in non-damaged WT and Mdm2S394A thymi (Figure 1C),
a reduction in IR activation of p53 target genes was seen in
Mdm2S394A thymi. Reduced expression levels of Mdm2, the
cell-cycle regulator Cdkn1a (p21), and the pro-apoptotic genes
Puma, Noxa, and Bax are in agreement with reduced levels of
p21, Puma, and cleaved Caspase-3 protein (Figure 1A) and
with a clear reduction in DNA-damage-induced apoptosis in
Mdm2S394A thymi following exposure of mice to low-level IR
(Figure 1D).
To explore whether these effects were unique to the
thymus, we also examined protein levels in spleens of WT and
Mdm2S394A mice. As observed in the thymus, there appeared
to be less total p53 in Mdm2S394A spleens before and after
irradiation (Figure S1), and Mdm2 levels were higher in both
untreated and irradiated Mdm2S394A spleens. Intriguingly, while
no induction of Mdm2 protein was observed in thymi of WT
and Mdm2S394A mice in response to IR, spleens of both geno-
types displayed a more ‘‘classic’’ induction of Mdm2 often
seen in cultured cells after genotoxic stress. Similar to what
was observed in the thymus, decreased levels of p53 and
increased levels of Mdm2 in irradiated Mdm2S394A spleens
correlate with reduced p53 activation (phospho-S18 p53),
reduced levels of Puma and p21, and reduced levels of cleaved
Caspase-3 (Figure S1).
ATM Phosphorylation of Mdm2-S394 Governs Mdm2
Levels and Stability
In order to directly analyze the effects of Mdm2-S394 phosphor-
ylation on the stability of Mdm2 in the presence and absence ofCell Reports 16, 2618–2629, September 6, 2016 2619
Figure 1. ATM Phosphorylation of Mdm2-
S394 Regulates Mdm2 Levels and p53
Activity
(A) WT andMdm2S394A mice were left untreated or
exposed to 1.75 Gy ionizing radiation (IR), and
thymi were harvested at 3 and 6 hr. Protein levels
were analyzed by western blotting. TKO indicates
Mdm2/, MdmX/, and p53/ control; Tg in-
dicates Mdm2Tg/+ Mdm2 overexpressing control.
(B) Thymus protein levels of biological triplicates of
WT and Mdm2S394A mice left untreated or treated
as in (A) for 3 hr were analyzed by western blotting.
Band intensities were determined by densitom-
etry. Mdm2 and p53 levels were normalized for
Vinculin levels and average values plotted (±SEM).
*p < 0.05, **p < 0.01 (Student’s t tests).
(C) Mice were treated as in (A), and fold expression
of p53-target genes was determined by real-time
qPCR, relative to untreated WT samples using
Rplp0 as internal reference (n = 3, ± SEM). *p <
0.05, **p < 0.01 (Student’s t tests).
(D) TUNEL staining of thymi frommice treated as in
(A). Scale bars represent 100 mm.exogenous DNA damage, we measured the half-life of Mdm2
proteins using the protein synthesis inhibitor cycloheximide.
Although basal levels of Mdm2 transcription are similar in WT
and Mdm2S394A thymi, Mdm2 protein levels are elevated in
non-damagedMdm2S394A mice (Figures 1A and 1B), suggesting
that the mutant Mdm2 protein is more stable in the absence of
exogenous DNA damage. However, we observed no significant
difference in the half-lives of WT Mdm2 and Mdm2S394A in un-
treated thymocytes (80 and 65 min, respectively, overlapping
95% confidence intervals) (Figure 2A). But following treatment
of the thymocytes with 2.5 Gy IR, the half-life of WT Mdm2
decreased by more than 50% (29 min), whereas the half-life of
Mdm2S394A remained unchanged (69 min) (Figure 2B). These
data show that phosphorylation of Mdm2-S394 by ATM is a
crucial event in DNA-damage-induced destabilization of Mdm2
under physiological conditions. As previous studies have shown
ATM phosphorylation of Mdm2 to impact the ability of Mdm2 to2620 Cell Reports 16, 2618–2629, September 6, 2016promote p53 degradation (Maya et al.,
2001; Cheng et al., 2009, 2011), we also
examined whether p53 stability was
affected in the presence and absence of
DNA damage.We observed no difference
in the half-life of p53 in non-treated WT
versus Mdm2S394A thymocytes (Fig-
ure S2A). As expected, DNA damage
stabilized p53 levels in WT cells (Fig-
ure S2B). Likewise, DNA damage stabi-
lized p53 levels in Mdm2S394A thymo-
cytes, albeit to a lower level than seen in
WT thymocytes.
Since we observed no difference in the
rate of p53 decay in Mdm2S394A and WT
thymocytes, it is possible that phosphor-
ylation of Mdm2-S394 upregulates p53
activity not only by altering p53 proteinstability but also by inhibiting Mdm2-p53 complex formation
and Mdm2-mediated steric inhibition of p53 transcriptional acti-
vation. Therefore, we examined the effects of Mdm2-S394 phos-
phorylation on Mdm2-p53 binding in the presence and absence
of DNA damage in whole tissue extracts. In an effort to control for
potential differences in antibody affinity following IR-induced
modification of Mdm2, Mdm2 was immunoprecipitated from un-
treated and irradiated thymus lysates in separate experiments
with two distinct antibodies whose epitopes reside in opposing
termini of Mdm2 (Figure 2C, left). In both cases, more p53
co-immunoprecipitated with Mdm2S394A than WT Mdm2 in un-
treated thymi, whereas similar amounts of p53 co-immunopre-
cipitated with Mdm2 in irradiated Mdm2S394A and WT thymi.
As there was less p53 observed in the total lysates of untreated
and irradiatedMdm2S394A thymi relative to WT thymi (Figure 2C,
right), this result reveals increased levels of Mdm2-bound p53
(relative to total p53) in undamaged and IR-treated Mdm2S394A
Figure 2. ATM Phosphorylation of Mdm2-
S394 Regulates Mdm2 Stability and Levels
of Mdm2-Bound p53
(A) Thymocytes harvested from WT and
Mdm2S394A mice (n = 6) were treated with 100 mg/
ml cycloheximide and harvested at the indicated
time points. The levels of Mdm2 and a-tubulin
were analyzed by western blotting. Band in-
tensities were determined by densitometry, and
Mdm2 levels normalized to a-tubulin were plotted.
One-phase decay curves were fitted using
GraphPad Prism software.
(B) Thymocytes harvested from WT and
Mdm2S394A mice (n = 6–8) were exposed to 2.5 Gy
IR and treated as in (A).
(C) Thymus protein extracts from mice untreated
or exposed to 5 Gy IR were immunoprecipitated
with antibodies for Mdm2 (NBP1-02158 (Ab-I) and
Ab-5 (Ab-II)) and p53. Immunoprecipitates were
analyzed by western blotting for Mdm2 and p53.
Total lysate (10% input) was analyzed by western
blotting.thymi. We confirmed this finding by performing the reciprocal
experiment using p53 immunoprecipitation, and observed that
equivalent amounts ofMdm2 co-immunoprecipitated with lesser
amounts of p53 in untreated and irradiated Mdm2S394A thymi.
Additional immunoprecipitation experiments against MdmX de-
tected no effect on the relative amounts of Mdm2-bound MdmX
or p53-bound MdmX before or after DNA damage (Figure S3).
Collectively, these data reveal that phosphorylation of Mdm2-
S394 under basal conditions and following acute IR exposure re-
duces Mdm2 stability, thereby reducing the relative amount of
Mdm2-bound p53. This reduction in Mdm2-p53 complex nega-
tively impactsMdm2 inhibition of p53 target gene transactivation
as well as Mdm2 destabilization of p53.
Accelerated Em-myc Driven Lymphomagenesis in
Mdm2S394A Mice
We have previously described an increased susceptibility to
spontaneous tumorigenesis in Mdm2S394A mice (Gannon et al.,
2012). We next sought to examine the effects of Mdm2-S394Cell Reportphosphorylation on oncogene-induced
tumorigenesis. Mdm2S394A mice were
bred to Em-myc transgenic mice
to generate Em-myc and Em-myc;
Mdm2S394A mice. Em-mycmice succumb
to pre-B/B cell lymphomas within
3–6 months of age. We observed a
median time to tumor presentation of
126 days in Em-myc mice, consistent
with previous studies (Adams et al.,
1985; Eischen et al., 1999; Sluss et al.,
2010) (Figure 3A). In contrast, the median
time to tumor presentation in Em-myc;
Mdm2S394A mice was only 71 days. This
represents a nearly 50% reduction in the
time to Myc-induced tumorigenesis
when ATM phosphorylation of Mdm2-S394 is inhibited. All tumor-bearing Em-myc mice and Em-myc;
Mdm2S394A mice presented with enlarged lymph nodes and
spleens, and representative tumors were examined histologi-
cally by H&E staining. Both genotypes developed similar, high-
grade lymphomas, composed of monotonous populations
of pre-B/B cells. Tumors displayed high levels of mitosis and
apoptosis and the characteristic ‘‘starry-sky’’ pattern resultant
from abundant tingible body-laden macrophages. The cell type
was further confirmed by immunohistochemistry (IHC) through
positive staining for B220/CD45R (Figure 3B).
Myc-driven B cell tumors face selective pressure to inactivate
the p53 pathway through p53 mutation, Mdm2 overexpression,
or by loss of Arf (Eischen et al., 1999). We examined the status
of p53, Mdm2, and Arf in a panel of 10 tumors that developed
in Em-myc;Mdm2S394A mice (Figure 3C). No marked differences
in p53 protein levels were observed in any of the 10 tumors
examined. However, Arf levels appeared more variable, with
loss of detectable Arf protein seen in 4 of the 10 tumors. RT-
PCR confirmed that three of those four tumors did not expresss 16, 2618–2629, September 6, 2016 2621
Figure 3. Accelerated Em-myc Driven Lymphomagenesis in
Mdm2S394A Mice
(A) Kaplan-Meier survival curves of Em-Myc (n = 16) and Em-Myc;Mdm2S394A
(n = 11) mice. Median survival times were as follows: Em-Myc (125.5 days)
and Em-Myc;Mdm2S394A (71 days). Curves were compared by log rank test:
p < 0.0001.
(B) Representative B cell lymphomas in lymph nodes of Em-Myc (98 days) and
Em-Myc;Mdm2S394A (80 days) mice were stained by H&E (top) and with an
antibody specific for B220 (bottom). Scale bars represent 100 mm.
(C) The levels of Mdm2, p53, and Arf were analyzed by western blotting in a
panel of Em-Myc;Mdm2S394A tumors. RT-PCR confirmed that full-length Arf
message was absent in 3 of 10 tumors (second from bottom). p53 cDNA was
sequenced for each tumor, revealing no mutations (bottom). LN, lymph node;
Spl, spleen.
(D) Schematic outlining the proposed methods of p53 activation by Myc.
Tumors in mice in which Mdm2 is WT select for loss of Arf or p53, or Mdm2
overexpression (Eischen et al., 1999). We propose that Mdm2S394A mice
obviate the need for p53 loss or Mdm2 overexpression by mitigating the
effects of the DDR arm of Myc signaling to p53.
2622 Cell Reports 16, 2618–2629, September 6, 2016full-length Arf mRNA. Arf levels have been shown previously to
be elevated in cases where p53 is mutant and the negative feed-
back loop between p53 and Arf is disrupted, and we identified
several tumors wherein Arf appeared to be increased. However,
sequencing of the entire p53 coding sequence of all 10 tumors
revealed no mutations in p53 gene transcripts. Thus, the
observed variability in Arf levels within the Myc tumors was not
a result of p53 status. Furthermore, Mdm2 protein levels did
not vary significantly between tumors, and qPCR analysis also
failed to detect alterations inMdm2 transcript levels in any tumor
(data not shown). Thus, ATM phosphorylation of Mdm2-S394
strongly suppresses Myc oncogene-induced tumorigenesis in
mice, and inhibition of this signaling event obviates the need
for mutation of the Mdm2-p53 tumor suppressor axis in Myc-
driven B cell lymphomagenesis (Figure 3D).
Mdm2S394A Mice Are Resistant to IR-Induced
Lymphomagenesis
We next sought to examine the effects of ATM phosphorylation
of Mdm2-S394 on IR-induced tumorigenesis. Exposure of
mice to repeated low-dose IR promotes the development of
thymic lymphomas (Kaplan and Brown, 1952). This lymphoma-
genesis is significantly enhanced in the absence of p53 (Kemp
et al., 1994; Labi et al., 2010; Michalak et al., 2010). As we
have shown that IR-induced p53 activity is diminished in both
the thymus and spleen of Mdm2S394A mice, we anticipated a
heightened sensitivity to IR-induced lymphomagenesis in this
model. Cohorts of WT, Mdm2S394A, p53+/, and p53/ mice
were subjected to four weekly doses of 1.75 Gy IR and
monitored over time for tumor presentation. 89% of WT mice
developed lymphomas by 400 days, with a median survival of
197 days (Figure 4A), consistent with a previous study employing
this dosing strategy (Labi et al., 2010). Also consistent with
previous studies was the significant acceleration of lymphoma-
genesis observed in the absence of p53 (Kemp et al., 1994;
Labi et al., 2010; Michalak et al., 2010). All p53/ mice devel-
oped lymphomas within 151 days, with a median survival of
131 days, whereas all p53+/mice developed lymphomas within
167 days, with a median survival of 154 days. Surprisingly,
Mdm2S394A mice proved to be highly resistant to IR-induced
Figure 4. Mdm2S394A Mice Are Resistant to IR-Induced Lymphoma-
genesis
(A) Kaplan-Meier survival curves of WT (n = 20), Mdm2S394A (n = 19), p53+/
(n = 9), and p53/ (n = 7) mice exposed to 7 Gy cumulative IR. Median survival
timeswere as follows:WT (185 days),Mdm2S394A (n.d.), p53+/ (154 days), and
p53/ (131 days). Curves were compared by log rank test: WT to p53/
(p < 0.0001), WT to p53+/ (p < 0.0001), WT to Mdm2S394A (p = 0.0007),
Mdm2S394A to p53+/ (p < 0.0001), and Mdm2S394A to p53/ (p < 0.0001).
(B) Representative tissue sections of lymphomas that developed in the
thymus, spleen, and liver of WT andMdm2S394A mice stained with H&E at 103
(left) and 403 (right) magnification. Scale bars represent 100 mm.thymic lymphomagenesis. Although tumor presentation in
Mdm2S394A mice followed similar initial kinetics as observed in
WT mice, only 42% of Mdm2S394A mice developed lymphoma,
with a median survival among tumor-bearing mice of 184 days.
Tumor-bearing animals presented with profoundly enlarged
thymi, as well as frequent splenomegaly and hepatomegaly. His-
tological analyses of H&E stained tissues showed disorganized,
hyperplastic lymphatic tissues as well as significant lymphocyte
infiltration in portal regions of the liver (Figure 4B). IHC confirmed
that the lymphomas arising in IR-treated mice were T-cell-
derived, with positive staining for CD3 and negative staining for
B220 (Figures 4C and S4). Thus, in contrast to their increased
rate of spontaneous and oncogene-induced tumorigenesis,
Mdm2S394Amice are actuallymore resistant to radiation-induced
T cell lymphomagenesis than WT mice, despite having clear de-
fects in p53-mediated thymic apoptosis.
Radiation Resistance inMdm2S394A Mice Is Dictated by
Improved Bone Marrow Recovery after IR
We have previously reported that Mdm2S394A mice are resistant
to threshold-lethal doses (8 Gy) of radiation. To better under-
stand why ATM phosphorylation of Mdm2-S394 would promote
radiation-induced lymphomagenesis yet provide resistance to
acute radiation, we decided to examine further the response of
these mice to whole-body IR. The primary cause of lethality in
mice subjected to IR doses as high as 10 Gy is a p53-dependent
ablation of the bone marrow compartment, known as hemato-
poietic syndrome (Komarova et al., 2004). Previous reports
have revealed that even small changes in p53 activity can pro-
foundly impact the hematopoietic system (Mendrysa et al.,
2003; Terzian et al., 2007; Wang et al., 2011; Pant et al., 2013),
and hematopoietic failure phenotypes have previously been
described in mice bearing hypomorphic or reduced copies of
functional Mdm2 alleles (Mendrysa et al., 2003; Terzian et al.,
2007). Furthermore, several p53 target genes, including those
encoding p21 or Puma, have been implicated in governing the
radiosensitivity of murine bone marrow (Cheng et al., 2000; van
Os et al., 2007; Shao et al., 2010; Yu et al., 2010; Wang et al.,
2011; Pant et al., 2013).
To elucidate the basis for the acute radioresistance of
Mdm2S394A mice, we examined the expression of the p53-target
genesMdm2, p21,Puma, andNoxa by qPCR in the bonemarrow
of WT,Mdm2S394A, and p53/mice before and after irradiation
(Figure 5A). As we observed in the thymus, no differences were
present in the expression levels of any of the examined p53
target genes in untreated Mdm2S394A bone marrow. Similar
expression levels of the target genes were observed in untreated
p53/mice. Following whole-body treatment of mice with 5 Gy
IR, the expression levels of all four genes increased dramatically
in WT bone marrow, indicative of a strong p53 response. How-
ever, lower levels of p21, Puma, and Noxa transcripts were
detected in Mdm2S394A bone marrow, indicating reduced p53(C) Representative tissue sections of lymphomas that developed in the
thymus, spleen, and liver of WT and Mdm2S394A mice were stained with anti-
bodies specific for CD3 (left) and B220 (right). Scale bars represent 100 mm.
See also Figure S4.
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Figure 5. Threshold-Lethal Radiation
Resistance in Mdm2S394A Mice Is Dictated
by Improved Bone Marrow Recovery
following IR
(A) Fold expression of p53-target genes in bone
marrow of WT, Mdm2S394A, and p53/ mice,
untreated and 6 hr after 5 Gy IR, was determined
by real-time qPCR. Fold expression was calcu-
lated relative to untreated WT samples using
Rplp0 as internal reference (n = 3–4 mice, ± SEM).
*p < 0.05, **p < 0.01 (Student’s t tests of DDCt
values).
(B) H&E stained bone marrow from WT,
Mdm2S394A, and p53/mice exposed to 8 Gy IR.
Blue arrows indicate nascent hematopoietic cell
colonies. Scale bars represent 100 mm.
(C) Bone marrow sections from untreated and
9 days post-IR mice described in (B) were stained
with an antibody specific for TER-119. Scale bars
represent 100 mm.activity in this tissue. Although Mdm2 transcript levels did not
appear to be overtly reduced in irradiated Mdm2S394A bone
marrow, no induction of Mdm2, p21, or Puma transcription
was observed in the bone marrow of p53-deficient mice, point-
ing to the p53 dependence of their induction following irradiation.
We next examined the bone marrow of WT, Mdm2S394A, and
p53/ mice by H&E staining at intervals up to 9 days following
exposure to 8 Gy IR (Figure 5B). To our surprise, all mice exam-
ined showed a dramatic decrease in cellularity at 1 and 3 days
following irradiation, to the point where the three genotypes
were phenotypically indistinguishable. Although WT bone
marrow continued to display a progressive loss of cellularity at
day 6 after IR, large colonies of cells had appeared in the bone
marrow of Mdm2S394A and p53/ mice at this time (Figure 5B,
arrows). By 9 days post-IR, the colonies present in Mdm2S394A
and p53/ mice had expanded significantly and often bridged
the medullary cavity, whereas only a few smaller colonies were
observed in WT bone marrow. Immunohistochemical staining
for CD45 confirmed that the colonies were of hematopoietic
origin (data not shown). The timing of the increased bonemarrow
cellularity in Mdm2S394A and p53/ mice (but not in WT
mice) is likely significant, as it precedes by 1 day the onset of
mortality observed in WT mice treated with 8 Gy IR (Gannon
et al., 2012).2624 Cell Reports 16, 2618–2629, September 6, 2016It has been shown that mice under-
going hematopoietic recovery produce
primarily myeloerythroid cells, and mye-
loerythroid-restricted progenitors are suf-
ficient to confer radioprotection (Uchida
et al., 1994; Na Nakorn et al., 2002). We
further characterized the bone marrow
colonies by IHC staining for the erythroid
marker TER-119 (Figure 5C). Consistent
with previous findings, we found that
approximately 25% of nucleated bone
marrow cells and all mature erythrocytes
stained positive for TER-119 in the un-treated bone marrow of mice irrespective of their genotype
(Kina et al., 2000). However, at 9 days post-8 Gy IR treatment,
only the few remaining mature erythrocytes in the WT bone
marrow stained positive for TER-119, whereas all of the large
colonies present in Mdm2S394A and p53/ bone marrow were
predominantly TER-119 positive. Thus, the p53-dependant
resistance to hematopoietic syndrome observed in Mdm2S394A
and p53/ mice following whole-body IR is linked to the
increased capability of these models to repopulate their
erythroid cell compartment.
Radiation Resistance inMdm2S394A Mice Is Governed by
Hematopoietic Stem and Progenitor Cells
In order to characterize the cell type responsible for the increase
in bone marrow repopulation and subsequent radioresistance
observed in Mdm2S394A mice, we utilized flow cytometry to
examine total bone marrow harvested 24 hr after treatment
with IR. No differences were observed in the numbers of line-
age-defined, mature hematopoietic cells in untreated WT or
Mdm2S394A mice (Figure 6A). Furthermore, no differences were
observed in the numbers of mature hematopoietic cells in irradi-
ated WT or Mdm2S394A bone marrow, save for slightly higher
numbers of surviving B cells (p = 0.046) in Mdm2 mutant mice.
These results are in keeping with the lack of a histopathological
Figure 6. Radiation Resistance in
Mdm2S394A Mice Is Governed by HSPCs
(A) Quantification of lineage-defined hematopoi-
etic cells in bone marrow of WT and Mdm2S394A
mice in the absence of treatment (top) and
24 hr after exposure to 5 Gy IR (bottom) (n = 3–
4, ± SEM).
(B) Quantification of LSK (CMP) and LSK
(HSPC) hematopoietic progenitor cells in bone
marrow of WT and Mdm2S394A mice described
in (A).
(C) Schematic showing the experimental design of
bone marrow repopulation assays. PB, peripheral
blood; BM, bone marrow.
(D) Leukocyte marker analysis of peripheral blood
of recipient mice described in (C) at 4 (n = 15), 8
(n = 15), and 10 (n = 5) weeks after bone marrow
transplantation (±SEM).
(E) Leukocyte marker analysis of total bone
marrow of recipient mice described in (C), un-
treated, 1 and 12 days after exposure to 5 Gy IR
(n = 5, ± SEM).
*p < 0.05, **p < 0.01 (Student’s t tests).difference in the initial loss of cellularity in irradiated WT and
Mdm2S394A bone marrow. In addition, no difference was
observed in the numbers of LinSca1cKit+ (LSK) common
myeloid progenitors (CMPs) in untreated WT and Mdm2S394A
bone marrow or in WT and Mdm2S394A bone marrow following
irradiation (Figure 6B). This was confirmed by in vitro colony
forming assays performed using the bone marrow of untreated
and irradiated WT andMdm2S394A mice (Figure S5). While there
was no difference in the numbers of LinSca1+cKit+ (LSK) he-
matopoietic stem and progenitor cells (HSPCs) in untreated WT
and Mdm2S394A bone marrow, there were significantly more
HSPCs present in Mdm2S394A bone marrow than in WT bone
marrow following irradiation (Figure 6B). This finding indicates
that the radioresistance observed in Mdm2S394A mice is due to
reduced loss and/or increased function of HSPCs in this model
following IR exposure.
We further examined the HSPCs of Mdm2S394A mice by per-
forming in vivo competitive repopulation assays. Mdm2S394A
bone marrow expressing the CD45.2 leukocyte marker and WT
bone marrow expressing the CD45.1 leukocyte marker were
transplanted in a 1:1 ratio into lethally irradiated WT (CD45.1)
recipient mice (Figure 6C). Peripheral blood analysis at 4, 8,
and 10 weeks following transplantation showed gradually
increasing relative contributions to the hematopoietic lineage
ofMdm2S394A bone marrow (62%, 69%, and 72%, respectively)Cell Report(Figure 6D). This indicated that
Mdm2S394A HSPCs have an inherent
advantage relative to WT HSPCs in their
ability to repopulate the hematopoietic
compartment of lethally irradiated mice.
In addition, we irradiated a cohort of the
same bone marrow-chimeric mice at
8 weeks post-transplantation and as-
sayed the relative contributions of WT
and Mdm2S394A bone marrow 1 and12 days later (Figure 6E). Relative contributions of 21% WT
and 78% Mdm2S394A were observed in the untreated bone
marrow of reconstituted mice. No significant changes were
observed in the percentages of WT and Mdm2S394A bone
marrow at 1 day after IR (18% and 81%, respectively). However,
a significant shift toward a greater proportion of Mdm2S394A
bone marrow was observed (8%WT, 91%Mdm2S394A) in the re-
constituted mice 12 days after IR. These results confirm that
Mdm2S394A HSPCs have a greater capacity to repopulate irradi-
ated bone marrow and determine that Mdm2S394A HSPCs
display greater stem cell function after genotoxic insult. Further-
more, increased Mdm2S394A HSPC cell function is cell-autono-
mous, as Mdm2S394A HSPCs outperform WT HSPCs in a WT
microenvironment.
DISCUSSION
Upon exposure to ionizing radiation, the activated ATM effector
kinase induces the phosphorylation of multiple signaling mole-
cules involved in the DDR, including the p53 tumor suppressor
protein and its chief negative regulator, Mdm2. This signaling
cascade has been proposed by many groups to activate p53
by interrupting Mdm2 inhibition of p53, thereby facilitating p53
transactivation of downstream target genes whose products
manifest the cellular response to DNA damage. Previously, wes 16, 2618–2629, September 6, 2016 2625
have shown that phosphorylation of p53 serine 18 in mice
following DNA damage has only a modest role in regulating
p53-mediated apoptosis and in governing p53 tumor suppres-
sion, whereas ATM phosphorylation of Mdm2 serine 394
following DNA damage regulates the amplitude and the duration
of the DDR in mice and alters p53 suppression of spontaneous
tumorigenesis (Sluss et al., 2004; Gannon et al., 2012). These
studies demonstrate in vivo the importance of Mdm2 phosphor-
ylation in ATM regulation of the p53 DDR.
In our present study, we explore in vivo the mechanism by
which Mdm2 phosphorylation alters p53 functions and examine
whether ATM-Mdm2-p53 signaling regulates tumorigenesis in
mice induced by activated oncogenes or ionizing radiation.
Mdm2 is present at higher levels in the thymus and spleen of
Mdm2S394A mice following DNA damage (Figures 1A, 2A, and
S1). These elevatedMdm2 levels are the result ofMdm2S394A be-
ing more stable following DNA damage (Figure 2C), as Mdm2
transcript levels are equivalent or even slightly reduced in IR-
treated Mdm2S394A tissues during this time frame (Figure 1C).
Although we previously found no difference in the stability of
phosphorylated Mdm2 after DNA damage (Gannon et al.,
2012), using newer and well-validated Mdm2 antibodies and
reduced radiation dosages (to promote recovery of the damaged
cells), we now find that Mdm2-S394 phosphorylation indeed de-
stabilizes Mdm2 in vivo. Our result is in keeping with previous
in vitro studies that indicate a decrease in the half-life of Mdm2
after genotoxic stress (Stommel and Wahl, 2004; Itahana et al.,
2007; Inuzuka et al., 2010). Our data provide direct, in vivo
evidence that DNA-damage-induced phosphorylation of Mdm2
at this single residue by ATM induces Mdm2 destabilization.
Furthermore, our data indicate that Mdm2 levels are elevated
in thymi and spleens of Mdm2S394A mice even in the absence
of acute, exogenous DNA damage (Figures 1A and S1). We
interpret this finding to be indicative of some basal level of
ATM activity in unstressed tissues that exerts influence on native
Mdm2 protein stability.
It is presently unclear how Mdm2 phosphorylation facilitates
Mdm2 destabilization. DNA-damage-induced degradation of
Mdm2 has been shown to occur even in the absence of Mdm2
E3 ligase activity (Itahana et al., 2007), and studies have identi-
fied the F-box proteins b-TRCP and FBXO31 as mediators of
Mdm2 degradation by the SCF complex (Inuzuka et al., 2010;
Malonia et al., 2015). Since FBXO31 is phosphorylated by ATM
and was recently found to interact with Mdm2 in a manner
dependent on ATM phosphorylation of Mdm2 (Santra et al.,
2009; Malonia et al., 2015), it is plausible that ATM phosphoryla-
tion of Mdm2-S394 in IR-treated mice results in FBXO31-
induced destabilization of Mdm2. Unfortunately, our attempts
to assay Mdm2-FBXO31 interactions in whole tissues before
and after DNA damage have proven unsuccessful. Thus, the
precise mechanism of how ATM phosphorylation of Mdm2-
S394 promotesMdm2 degradation under physiologic conditions
remains to be determined.
The increased levels of Mdm2 observed in the spleen and
thymus of Mdm2S394A mice after DNA damage correlate with
decreased p53 levels and p53 activity in these Mdm2S394A tis-
sues. Previous studies have suggested that ATM phosphoryla-
tion of the analogous residue on human MDM2 (S395), either2626 Cell Reports 16, 2618–2629, September 6, 2016alone or in combination with several other ATM-target serine res-
idues in the same region, impacts Mdm2’s ability to promote p53
degradation and nuclear export and governs RING-domain olig-
omerization and polyubiquitination of p53 (Maya et al., 2001;
Cheng et al., 2009). DNA damage resulted in p53 stabilization
in WT thymocytes, albeit after a brief period of p53 degradation
(Figure S2B). While the initial rate of p53 degradation does
not appear affected in irradiated Mdm2S394A thymocytes, we
observed a prolonged period of p53 destabilization, ultimately
resulting in lower relative levels of p53. This prolonged p53
destabilization may reflect the increased stability of Mdm2S394A
after DNA damage. This is supported by the increased relative
amounts of Mdm2-bound p53 after IR observed in Mdm2S394A
thymi (Figure 2C). However, it remains possible that increased
DNA-damage-induced p53 activity in WT thymi is caused not
only by reduced Mdm2-mediated p53 degradation (due to
destabilization of Mdm2) but also by reduced Mdm2 steric
inhibition of p53. As Mdm2 binds to the amino-terminal, tran-
scriptional activation domain of p53 and inhibits p53 target
gene expression, reduced Mdm2-p53 complex formation after
Mdm2 phosphorylation by ATM may account for the increase
in p53 activity even when p53 protein stability is only modestly
altered (Momand et al., 1992; Oliner et al., 1993).
The reduced level of p53 activity inMdm2S394A mice facilitates
more rapid B cell lymphomagenesis in Em-mycmice (Figure 3). It
has been previously demonstrated that activated oncogenes
such as Myc result in elevated Arf expression, a result of hyper-
proliferative signaling (Zindy et al., 1998; Sherr et al., 2005). The
importance of disrupting the Arf-Mdm2-p53 pathway in Myc-
driven lymphomagenesis is evidenced by the fact that Em-myc
driven tumors in mice face a selective pressure to inactivate the
p53 pathway, by either p53 mutation, Mdm2 overexpression, or
loss of Arf (Eischen et al., 1999). However, we observed a signif-
icant acceleration in the median time of tumor presentation in
Em-myc;Mdm2S394A mice in the absence of Mdm2 overexpres-
sion or p53mutation in tumors (Figures 3Aand3C). This suggests
that an absence of Mdm2-S394 phosphorylation is sufficient to
diminish p53 activity in response to oncogene activation and re-
duces the selective pressure to genetically disrupt the Mdm2-
p53 signaling axis (Figure 3D). Although loss of Arf was observed
in a subset of Em-myc;Mdm2S394A tumors, this finding likely re-
flects the ability of Arf to prevent tumorigenesis in Em-myc mice
through an Mdm2/p53 independent mechanism.
Although elevated Myc levels have been shown to result in
increased levels of cellular DNA damage, the relative contribu-
tions of the pro-proliferative effects and DNA-damage-induced
effects of Myc on tumor formation remain uncertain (Halazonetis
et al., 2008; Meek, 2015). To further explore a role for Mdm2
phosphorylation in the DDR and in regulation of p53 tumor sup-
pression, we examined lymphomagenesis induced by low level
exposure of mice to ionizing radiation (Figure 4). In contrast to
our results in Myc-driven lymphomagenesis, Mdm2S394A mice
proved to be more resistant to DNA-damage-induced T cell lym-
phomagenesis, highlighting a stark difference in the effects of
ATM-Mdm2-p53 signaling in lymphomas induced by different
types of DNA-damage-related stress.
The cell of origin in IR-induced lymphomas has historically
been viewed as a stem and/or progenitor cell residing within
the bone marrow (Kaplan, 1964), and IR-induced lymphoma-
genesis is significantly enhanced in the absence of functional
p53 (Kemp et al., 1994). Subsequent studies examining the
contribution of the p53-dependent pro-apoptotic genes Puma
and Noxa made the paradoxical observation that Puma/
mice develop fewer IR-induced lymphomas (Labi et al., 2010;
Michalak et al., 2010). This was attributed to increased survival
of leukocytes in the bone marrow, which reduced the prolifera-
tive stress and/or propagation of lesions within progenitor cells
tasked with repopulating the bone marrow. That Noxa/ mice
displayed only modest radioprotection of LSK cells and devel-
oped more lymphomas was interpreted as a failure to clear
damaged progenitors, thereby promoting the survival of
damaged stem and/or progenitor cells (Michalak et al., 2010).
Despite a reduction of p53-dependent gene expression of
Puma and Noxa in total bone marrow of IR-damaged
Mdm2S394 mice (Figure 5A), we observed no defects in the
attrition of mature hematopoietic cells or lineage-defined pro-
genitor cells (CMPs) (Figures 6A and 6B). Only the most primi-
tive HSPCs display resistance to IR (Figure 6B). Our finding that
Mdm2S394A mice are resistant to IR-induced lymphomas re-
veals that the effects of a reduced p53-dependent damage
response in Mdm2S394A mice does not mirror the ablation of
either Puma or Noxa alone. Interestingly, a recent study by
Lee et al. (2015) suggests that the tumor-initiating cell in IR-
induced lymphomas is thymic in origin. Using mice in which
p53 activity was temporally blocked during total-body irradia-
tion, the authors propose that the IR-induced p53 response in
bone marrow promotes lymphomagenesis by reducing HSPC
fitness, thereby reducing the competition of cells originating
from the bone marrow with thymocytes containing oncogenic
lesions. The results we have observed with Mdm2S394A mice
align favorably with this model, as we have observed less
p53 activity and increased HSPC fitness in Mdm2S394A mice
following threshold-lethal doses of radiation and observed
reduced incidence of T cell lymphomagenesis in Mdm2S394A
mice after IR exposure (Figures 5 and 6). The p53 dependence
of the increased HSPC fitness in Mdm2S394A mice is further
intimated by studies that have observed increased bone
marrow repopulation potential in bone marrow deficient for
p53, both in the presence and absence of IR (reviewed in
Pant et al., 2012). Interestingly, a recent study has linked
Mdm2 to enhanced stem-ness via association with the Poly-
comb Repressor Complex 2 (PRC2) (Wienken et al., 2016).
Further studies into the relative p53-dependent and p53-
independent contributions of Mdm2 to HSPC fitness are clearly
warranted.
We conclude that ATM phosphorylation of Mdm2-S394 is crit-
ical for Mdm2 degradation and robust p53 activation after DNA
damage. Our results show that while ATM’s regulation of p53 ac-
tivity through Mdm2 is critical in preventing oncogene-induced
tumorigenesis, disrupting this regulation imparts protection
from bonemarrow ablation and lymphomagenesis resulting after
DNA damage. These observations are of clinical significance, as
they suggest that the temporal inhibition of Mdm2 phosphoryla-
tion by short-acting kinase inhibitors or by use of excess decoy
ATM target-sites (amolecular sponge of sorts) would reduce p53
activation and alleviate the toxicity associated with radiother-apies. Our results further indicate that such treatment would
likely protect against the subsequent development of secondary
hematological malignancies induced by exposure to ionizing
radiation.
EXPERIMENTAL PROCEDURES
Mice and Animal Studies
All animals described in this study were on a C57Bl/6 background. Mice and
cells were irradiated with a cesium-137 source (Gammacell 40). The genera-
tion of Mdm2S394A mice has been previously described (Gannon et al.,
2012). Em-Myc mice were a gift from Christine Eischen (Vanderbilt University).
Mice in Em-Myc tumor assays were virgin and inherited the Em-Myc allele
paternally. For IR-induced tumor assays, mice 31 ± 3 days of age were irradi-
ated weekly with 1.75 Gy for 4 weeks (7 Gy cumulative dose). For bonemarrow
transplantation experiments, recipient CD45.1 mice received 11 Gy of whole-
body irradiation in a split dose (2 3 5.5 Gy, 4 hr apart). Irradiated recipients
were reconstituted by intravenous (i.v.) injection of 23 106 bone marrow cells
(1:1 mixture of WT and Mdm2S394A). All animals used in this study were main-
tained and assayed in accordance with federal guidelines and those estab-
lished by the Institutional Animal Care and Use Committee at the University
of Massachusetts Medical School.
Protein Analysis
Tissues and cells were lysed in NP-40 lysis buffer or in CelLytic MT Cell Lysis
Reagent (Sigma), supplemented with protease and phosphatase inhibitors.
Protein extracts were analyzed by western blotting or immunoprecipitation
and western blotting. A detailed description of the methods employed,
including antibodies and clones, is provided in the Supplemental Experimental
Procedures.
Gene Expression Analysis and Sequencing
Total RNA was isolated from tissues by RNeasy mini kit (QIAGEN) and cDNA
synthesized by Superscript III First Strand Synthesis System (Invitrogen).
qPCR was performed using SYBR Select Master Mix (Applied Biosystems)
in conjunction with a 7300 Real-Time PCR System (Applied Biosystems).
A detailed description of the methods employed, including primer sequences,
for qPCR, RT-PCR, and sequencing is provided in the Supplemental Experi-
mental Procedures.
Histopathology
Tissues sampleswere fixed in 10% formalin for 24 hr. The UMMSDiabetes and
Endocrinology Research Center Morphology Core performed embedding,
sectioning, and staining. TUNEL staining was performed using the In Situ
Cell Death Detection Kit, POD (Roche), according to manufacturer’s instruc-
tions. IHC was performed with antibodies specific for B220 (550286; BD
Pharmingen), CD3 (A0452; Dako), and TER-119 (553671; BD Pharmingen).
Stained tissue was analyzed using an Olympus CX41 microscope fitted with
a PixeLINK camera and software.
Flow Cytometry
Total bone marrow from both hind limbs was harvested, red blood cells were
lysed, and single-cell suspensions were stained with cell-surface antibodies
for Gr-1, CD11B, CD3, and B220. For LSK analysis, bone marrow cells were
stained with a biotin lineage mixture and were stained with antibodies for
Sca-1, c-Kit, CD34, and Flk2. To distinguish between WT and Mdm2S394A
hematopoietic cells in the reconstitution studies, peripheral blood and bone
marrow were stained with antibodies specific for CD45.1 and CD45.2. All sam-
ples were run on a BD LSRII flow cytometer (BD Bioscience) and analyzed us-
ing FlowJo software (Tree Star). A complete list of antibodies including clone
numbers is given in Table S1.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism software v.6.0d.
Kaplan-Meier survival curves were analyzed by log rank test. A p value
of <0.05 was considered statistically significant for Student’s t tests.Cell Reports 16, 2618–2629, September 6, 2016 2627
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